Payment overview · 2025
General Payments
$548.23
31 reported records · 10 companies
Healthcare provider profile · identity verified
William D Astin, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRISTOL, TN · NPI 1356310759
Verified facts
What the public records show
CMS Open Payments records show William D Astin, MD received $548.23 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Prolia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $147.59 | 26.9% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $75.84 | 13.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.27 | 12.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.92 | 12.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.68 | 11.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.32 | 9.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.35 | 5.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.94 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.70 | 2.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.62 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $548.23 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.95 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.79 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $75.84 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.27 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.27 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.68 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.32 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.07 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.35 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 19 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
99 | 18 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 676 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 505 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 434 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 105 |
| Omeprazole | Omeprazole | 403 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 381 | 100 |
| Metformin Hcl | Metformin Hcl | 373 | 91 |
| Gabapentin | Gabapentin | 329 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 326 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 288 | 68 |
| Meloxicam | Meloxicam | 260 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 248 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 58 |
| Eliquis | Apixaban | 245 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 54 |
| Furosemide | Furosemide | 232 | 61 |
| Sertraline Hcl | Sertraline Hcl | 226 | 45 |
| Allopurinol | Allopurinol | 212 | 51 |
| Tramadol Hcl | Tramadol Hcl | 207 | 37 |
| Trazodone Hcl | Trazodone Hcl | 194 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 45 |
| Simvastatin | Simvastatin | 178 | 44 |
| Clonazepam | Clonazepam | 169 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 165 | 41 |
| Potassium Chloride | Potassium Chloride | 163 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 161 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 160 | 42 |
| Losartan Potassium | Losartan Potassium | 136 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 36 |
| Jardiance | Empagliflozin | 132 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 25 |
| Glimepiride | Glimepiride | 123 | 30 |
| Prednisone | Prednisone | 123 | 66 |
| Carvedilol | Carvedilol | 109 | 23 |
| Celecoxib | Celecoxib | 108 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 26 |
| Famotidine | Famotidine | 100 | 24 |
| Synthroid | Levothyroxine Sodium | 99 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 19 |
| Montelukast Sodium | Montelukast Sodium | 97 | 26 |
| Bupropion Xl | Bupropion Hcl | 96 | 26 |
| Pregabalin | Pregabalin | 96 | 16 |
| Ibuprofen | Ibuprofen | 95 | 25 |
| Valsartan | Valsartan | 95 | 26 |
| Metformin Hcl Er | Metformin Hcl | 91 | 21 |
| Lorazepam | Lorazepam | 82 | 21 |
| Mounjaro | Tirzepatide | 82 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 78 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 23 |
| Benazepril Hcl | Benazepril Hcl | 74 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 12 |
| Alprazolam | Alprazolam | 70 | 12 |
| Terazosin Hcl | Terazosin Hcl | 69 | 17 |
| Baclofen | Baclofen | 68 | 12 |
| Estradiol | Estradiol | 62 | 15 |
| Ozempic | Semaglutide | 61 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 60 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | suppressed |
| Atenolol | Atenolol | 57 | 16 |
| Azithromycin | Azithromycin | 57 | 49 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Mirtazapine | Mirtazapine | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 20 |
| Ezetimibe | Ezetimibe | 53 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 53 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 45 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | 15 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 12 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Levemir Flexpen | Insulin Detemir | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 29 |
| Diazepam | Diazepam | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 12 |
| Cephalexin | Cephalexin | 37 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 25 |
| Methocarbamol | Methocarbamol | 36 | 12 |
| Nystatin | Nystatin | 36 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Nabumetone | Nabumetone | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 21 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Cefdinir | Cefdinir | 30 | 22 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 15 |
| Ondansetron Odt | Ondansetron | 20 | 12 |
| Klor-Con M10 | Potassium Chloride | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Prolia | Denosumab | 19 | 11 |
| Torsemide | Torsemide | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $548.23 · 31 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, EVENITY, MOUNJARO, Ozempic, PROLIA, QULIPTA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error